Mega Genomics Completes Hong Kong IPO

Hong Kong and Shanghai – Paul Hastings, a leading global law firm, announced today that the firm has advised Mega Genomics Limited, the largest consumer genetic testing platform in China in terms of the cumulative number of tests administered, on its HK$215 million global offering and IPO on the Main Board of the Hong Kong Stock Exchange. China Securities (International) Corporate Finance Company Limited acted as the sole sponsor for this transaction.

Mega Genomics Limited is a leading full-spectrum genetic testing platform in China for consumer genetic testing, cancer screening, nutrition and metabolism, chronic disease susceptibility, and pharmacogenetic and infectious disease testing.

With an industry-leading expertise in Hong Kong capital markets, Paul Hastings has advised on some of the most representative biotech and healthcare companies in their listings in Hong Kong in recent years, including a biopharmaceutical company SciClone Pharmaceutical, a Hong Kong-based biopharmaceutical company SinoMab BioScience Limited (listed under Chapter 18A), an assisted reproductive services company Jinxin Fertility Group, a Chinese vaccine company CanSino Biologics Inc. and a Chinese biotech company Ascletis Pharma (the first listing under Chapter 18A).

The Paul Hastings team was led by Jia Yan and David Wang, co-chairs of the firm’s mainland China offices, and Corporate partner Samuel Ng, with support from associates Devin Geng, Nancy Sun, Stefan Chan and Stephen Chow, China associates Lanxin Zhang and Julia Hu, and China advisor Yanqiu Yang.

About Paul Hastings

Dedicated to providing intellectual capital and superior execution to the world’s leading Wall Street and global investment banks, asset managers and corporations achieve their business and legal goals, Paul Hastings is a premier global finance law firm with elite teams in finance, mergers and acquisitions, private equity, and litigation. We are one of only a handful of law firms ranked across multiple core finance areas including: structured credit, leveraged finance, private credit, capital markets, and real estate finance.

Paul Hastings is ranked as one of the top firms in the world in The American Lawyer’s “Premier League” for momentum, profit and prestige amongst firms in the 2022 American Lawyer 100.